- Home
- RIME vs LIXT Comparison
RIME vs LIXT Comparison
Compare RIME & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIME
- LIXT
- Stock Information
- Founded
- RIME 1982
- LIXT 2005
- Country
- RIME United States
- LIXT United States
- Employees
- RIME N/A
- LIXT N/A
- Industry
- RIME
- LIXT Biotechnology: Pharmaceutical Preparations
- Sector
- RIME
- LIXT Health Care
- Exchange
- RIME NYSE
- LIXT Nasdaq
- Market Cap
- RIME 4.9M
- LIXT 4.2M
- IPO Year
- RIME 1994
- LIXT N/A
- Fundamental
- Price
- RIME $0.23
- LIXT $1.62
- Analyst Decision
- RIME
- LIXT
- Analyst Count
- RIME 0
- LIXT 0
- Target Price
- RIME N/A
- LIXT N/A
- AVG Volume (30 Days)
- RIME 790.7K
- LIXT 1.8M
- Earning Date
- RIME 11-26-2024
- LIXT 11-12-2024
- Dividend Yield
- RIME N/A
- LIXT N/A
- EPS Growth
- RIME N/A
- LIXT N/A
- EPS
- RIME N/A
- LIXT N/A
- Revenue
- RIME $37,788,657.00
- LIXT N/A
- Revenue This Year
- RIME N/A
- LIXT N/A
- Revenue Next Year
- RIME N/A
- LIXT N/A
- P/E Ratio
- RIME N/A
- LIXT N/A
- Revenue Growth
- RIME 24.99
- LIXT N/A
- 52 Week Low
- RIME $0.22
- LIXT $1.31
- 52 Week High
- RIME $1.97
- LIXT $4.42
- Technical
- Relative Strength Index (RSI)
- RIME N/A
- LIXT 43.04
- Support Level
- RIME N/A
- LIXT $1.56
- Resistance Level
- RIME N/A
- LIXT $1.87
- Average True Range (ATR)
- RIME 0.00
- LIXT 0.23
- MACD
- RIME 0.00
- LIXT -0.03
- Stochastic Oscillator
- RIME 0.00
- LIXT 8.33
About RIME ALGORHYTHM HOLDINGS INC
Algorhythm Holdings Inc is a holding company with two primary investments. It operates through its subsidiaries, one of which is an emerging leader in the AI-enabled global logistics industry. The other subsidiary is engaged in consumer karaoke products, Which designs and distributes the industry's widest assortment of at-home and in-car karaoke entertainment products.
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.